BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38266312)

  • 21. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
    Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
    Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
    Zhao M; Qi M; Li X; Hu J; Zhang J; Jiao M; Bai X; Peng X; Han B
    Prostate; 2019 Apr; 79(5):480-488. PubMed ID: 30609075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver X receptor activation inhibits PC-3 prostate cancer cells via the beta-catenin pathway.
    Youlin K; Li Z; Weiyang H; Jian K; Siming L; Xin G
    Pathol Res Pract; 2017 Mar; 213(3):267-270. PubMed ID: 28139275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
    Rodriguez-Bravo V; Pippa R; Song WM; Carceles-Cordon M; Dominguez-Andres A; Fujiwara N; Woo J; Koh AP; Ertel A; Lokareddy RK; Cuesta-Dominguez A; Kim RS; Rodriguez-Fernandez I; Li P; Gordon R; Hirschfield H; Prats JM; Reddy EP; Fatatis A; Petrylak DP; Gomella L; Kelly WK; Lowe SW; Knudsen KE; Galsky MD; Cingolani G; Lujambio A; Hoshida Y; Domingo-Domenech J
    Cell; 2018 Aug; 174(5):1200-1215.e20. PubMed ID: 30100187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.
    Hahm ER; Singh KB; Singh SV
    Cell Cycle; 2016 Sep; 15(17):2309-20. PubMed ID: 27341160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription.
    Liu S; Zheng Y; Zhang Y; Zhang J; Xie F; Guo S; Gu J; Yang J; Zheng P; Lai J; Yin L; Wang H
    Theranostics; 2020; 10(23):10634-10651. PubMed ID: 32929371
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
    Monga J; Subramani D; Bharathan A; Ghosh J
    Sci Rep; 2020 Apr; 10(1):6649. PubMed ID: 32313135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
    Wang J; Yang X; Li R; Wang L; Gu Y; Zhao Y; Huang KH; Cheng T; Yuan Y; Gao S
    Oncol Rep; 2018 Nov; 40(5):2814-2825. PubMed ID: 30132573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.
    Ciccarelli C; Di Rocco A; Gravina GL; Mauro A; Festuccia C; Del Fattore A; Berardinelli P; De Felice F; Musio D; Bouché M; Tombolini V; Zani BM; Marampon F
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1685-1699. PubMed ID: 29959569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
    Yan Y; Zhou B; Qian C; Vasquez A; Kamra M; Chatterjee A; Lee YJ; Yuan X; Ellis L; Di Vizio D; Posadas EM; Kyprianou N; Knudsen BS; Shah K; Murali R; Gertych A; You S; Freeman MR; Yang W
    Nat Commun; 2022 Feb; 13(1):669. PubMed ID: 35115556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.
    Lin TP; Li J; Li Q; Li X; Liu C; Zeng N; Huang JM; Chu GC; Lin CH; Zhau HE; Chung LWK; Wu BJ; Shih JC
    Mol Cancer Res; 2018 Dec; 16(12):1940-1951. PubMed ID: 30042175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.
    Li L; Ren C; Yang G; Fattah EA; Goltsov AA; Kim SM; Lee JS; Park S; Demayo FJ; Ittmann MM; Troncoso P; Thompson TC
    Cancer Res; 2011 Dec; 71(24):7694-704. PubMed ID: 22025562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer.
    Qiu J; Yang B
    Mol Cell Biochem; 2021 Jan; 476(1):1-10. PubMed ID: 32935296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of β-catenin.
    Liang T; Ye X; Liu Y; Qiu X; Li Z; Tian B; Yan D
    Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30532005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ANP32B promotes lung cancer progression by regulating VDAC1.
    Li T; Wang N; Li S; Yan H; Gao S; Gao W; Xu R
    Gene; 2023 Apr; 859():147200. PubMed ID: 36642319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin targets c-MYC oncogene to prevent prostate cancer.
    Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
    Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [PC-1 enhances c-myc gene expression in prostate cancer cells].
    Yu L; Shi QG; Qian XL; Li SH; Wang HT; Wang LL; Zhou JG
    Yi Chuan; 2010 Apr; 32(4):348-52. PubMed ID: 20423888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of 5-lipoxygenase selectively triggers disruption of c-Myc signaling in prostate cancer cells.
    Sarveswaran S; Chakraborty D; Chitale D; Sears R; Ghosh J
    J Biol Chem; 2015 Feb; 290(8):4994-5006. PubMed ID: 25540201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.
    White MA; Lin C; Rajapakshe K; Dong J; Shi Y; Tsouko E; Mukhopadhyay R; Jasso D; Dawood W; Coarfa C; Frigo DE
    Mol Cancer Res; 2017 Aug; 15(8):1017-1028. PubMed ID: 28507054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.